Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy.
Publication/Presentation Date
9-1-2024
Abstract
BACKGROUND: The real-world safety of robotic resections after neoadjuvant chemoimmunotherapy remains poorly defined in patients with non-small cell lung cancer. Due to reported increased operative challenges after neoadjuvant immunotherapy, we aim to describe our early institutional experience and outcomes after robotic resection in this clinical context.
METHODS: We performed a retrospective chart review of patients with non-small cell lung cancer who underwent a robotic lobectomy, comparing patients from June 1, 2022, through October 31, 2023, who were treated with neoadjuvant chemoimmunotherapy consistent with the Checkmate-816 protocol and a control group with upfront resection.
RESULTS: A total of 21 patients underwent neoadjuvant chemoimmunotherapy and robotic lobectomy in our cohort, and 64 patients were in the control group. Compared with control, the median tumor size was 3.2 cm vs 2.0 cm (
CONCLUSIONS: In our cohort, robotic-assisted lobectomy was safe and of comparable quality in the setting of neoadjuvant chemoimmunotherapy.
Volume
2
Issue
3
First Page
453
Last Page
457
ISSN
2772-9931
Published In/Presented At
Mack, S. J., Rshaidat, H., Ho, A., Till, B. M., Collins, M. L., Whitehorn, G. L., Martin, J., Jacob, J. D., Grenda, T. R., Evans, N. R., 3rd, & Okusanya, O. T. (2024). Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy. Annals of thoracic surgery short reports, 2(3), 453–457. https://doi.org/10.1016/j.atssr.2024.02.008
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
39790395
Department(s)
Administration and Leadership
Document Type
Article